Dagher L

Language: English
References: 22
Page: 36-39
PDF size: 48.42 Kb.

Text Extraction

Characteristics of prospective patients for treatment

Epidemiologic studies suggest that liver cirrhosis develops after 20 years of active infection with hepatitis C virus (HCV) and that hepatocarcinoma develops after about 30 years of active HCV infection. Liver cirrhosis may be compensated, in which case clinical and biochemical deterioration is absent, or it may be decompensated, in which case progressive deterioration of liver function is evident. Annual rates of decompensation, hepatocarcinoma, and death in patients with decompensated cirrhosis are 3.6%–6%, 1.4%–3.3%, and 2.6%–4%, respectively. Once cirrhosis becomes decompensate, the survival rate in the subsequent five years is 50%. The foregoing justifies recommending treatment for compensate cirrhotic patients with hepatitis C.
The safety and efficacy of treatment is acceptable for patients with a Child–Pugh (CP) score less than 7 or a model for end-stage liver disease (MELD) score less than 18 (Table I). Treatment of patients awaiting liver transplantation may be considered provided that it is administered by experienced clinical personnel and that strict vigilance for adverse effects is maintained.

REFERENCES

1. World Health Organization. Weekly epidemiological record 1999; 74: 421-8.

2. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-62.

3. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000; 31: 777-82.

4. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463-6.

5. Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, et al. Interrelationship of blood transfusion non-A, non-B hepatitis and hepatocellular carcinoma. Analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12: 671-5.

6. Planas R, Balleste B, Alvarez MA, Rivera M, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. Journal of Hepatology 2004; 40: 823-30.

7. Everson G. Management of cirrhosis due to chronic hepatitis C. Journal of Hepatology 2005; 42: S65-S74.

8. Wiesner R, Sorell M, Villamil F, and the International Liver Transplantation Society Expert Panel. Liver Transpl 2003; 9: S1-S9.

9. Murray K, Carithers R. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology 2005; 41: 1407-32.

10. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, et al. Peg-interferon alfa 2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 1673-80.

11. Fried MW, Shiffman ML, Reddy RK, Smith C, Marino G, Goncales F, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C infection. N Engl J Med 2002; 347: 975-82.

12. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman ML, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-65.

13. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.

14. Burroughs AK, Groszmann R, Bosch J, Grace N, Garcia Tsao G, Carcia-Pagan JC, et al. Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point? Gut 2002; 50: 425-7.

15. Ratti L, Pozzi M, Bosch J. Pathophysiology of portal hypertension in HCV-related cirrhosis: Putative role of assessment of portal pressure gradient in Peginterferon-treated patients. Article in Press. Digestive and Liver Disease.

16. Camma C, Di Bona D, Schepis F, Heathcote EJ, Zeuzem S, Pockros PJ, et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 2004; 39: 333-42.

17. Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, et al. Evolution of the HALT-C trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trial 2004; 25: 472-92.

18. Afdhal N, Freilich B, Levine R, Black M, Brown R, Monsour H, et al. Colchicine versus peg-interferon long-term (COPILOT) trial: interim analysis of clinical outcomes at year 2. Hepatology 2004; 40: 238A.

19. Curry M, Cardenas A, Afdhal NH. Effect of maintenance Peginterferon therapy on portal hypertension and its complications: results from the COPILOT study. Program and abstracts of the 40th Annual Meeting of the European Association for the Study of the Liver; April 13–17, 2005; Paris, France. Abstract 95.

20. Camma C, Di Bona D, Craxi A. The impact of antiviral treatments on the course of chronic hepatitis C: an evidencebased approach. Current Pharmacological Design 2004; 10: 2123-30.

21. Shiratori Y, Ito Y, Yoyosuka O, Imazeki F, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005; 142: 105-14.

22. Patheodoridis GV, Papadimitropoulos V, Hadzyiannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a metaanalysis. Aliment Pharmacol Ther 2001; 15: 689-98.